Abstract
The history of Alzheimer’s disease (AD) presents a difficulty in a book that is devoted to the cholinergic system. Indeed, this history emphasizes the tale of plaques and bundles; the heroes of the tale are Alois Alzheimer and Gaetano Perusini, and their discoveries concern the amyloid “cement”; this tale, told in section 1 of this introduction, does not seem to relate to cholinergicity. Similarly, as a whole, the chapter focuses on neurocellular degeneration and degenerative proteins as the basis of AD rather than on cholinergicity. Yet, there is a strong link between AD and the cholinergic system in view of the apparent preference of plaques, bundles, and degenerative proteins for the central cholinergic neurons. This matter and its consequences are discussed in section 2 of this introduction and expanded upon in section K (Wong et al., 2006).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adem, A. Nordberg, A., Bucht, G. and Winblad, B.: Nicotinic and muscarinic binding sites on lymphocytes of Alzheimer patients. En: “Alzheimer’s and Parkinson’s Diseases,” A. Fisher, I. Hanin, and C. Lachman, Eds., pp. 337–344, Plenum Press, New York, 1985.
Adler, G., Brassen, S. and Jajcevic, A.: EEG coherence in Alzheimer’s dementia. J. Neural. Transm. 110: 1051–1058, 2003.
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G. and Thai, L. J.: Alzheimer’s Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289(21): 2819–2826, 2003.
Alzheimer, A.: Über eine einartige Erkränkung der Hinmrinde. XXXVII Versammlung Südwest deutscher Irrenärzte in Tübingen, 4 Nov., 1906. Neurologishes Centralblatt,p. 1134, 1906.
Alzheimer, A.: Über eine einartige Krankheitsfälle des späteren Alters. Zeitshrft. Ges. Neurologie u. Psychiatrie 4: Heft 3, 1907.
Alzheimer, A.: Über die anatomische Grundlage der Hutingtonschen Chorea und der chore atischen Bewegungen überhaupt. Ztschrft. Ges. Neurol. Psychiat. 3: 566, 1911.
Alzheimer, A.: On certain peculiar diseases of old age. In: “History of Psychiatry,” Translated, with an Introduction by H. Foerstl and R. Levy, Alpha Academic Press, London, vol. 2, pp. 71–101, 1991.
Anand, R., Hartman, R. and Messina, J.: Long-term treatment with rivastigmine continues to provide benefits for up to one year. Fifth International Geneva-Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Abstract 18, 1998.
Anderson, J. P., Esch, F.S., Keim, P.S., Sambamurti, K., Lieberburg, I. and Robakis, N. K.: Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells. Neurosci. Lett. 128(1): 126–128, 1991.
Anderton, B. H., Betts, J., Blackstock, W. P., Brion, J. P., Chapman, S., Connell, J., Dayanandan, R., Gallo, J. M., Gibb, G., Hanger, D. P., Hutton, M., Kardalinou, E., Leroy, K., Lovestone, S., Mack, T., Reynolds, C. H. and Van Slegtenhorst, M.: Sites of phosphorylation in tau and factors affecting their regulation. Biochem. Soc. Symp. 2001(67): 73–80, 2001.
Aoki, M., Iwamoto-Sugai, M., Sugiura, I., Sasaki, C., Hasegawa, T., Okumura, C., Sugio, S., Kohno, T. and Matsuzaki, T.: Expression, purification and crystallization of human tau-protein kinase I/glycogen synthase kinase-3beta. Acta Crystallogr. D Biol. Crystallogr. 56, Pt. 11: 1464–1465, 2000.
Aoukati, A. and Tan, R.: Role for glycogen synthase kinase-3 in NK cell cytotoxicity and X-linked lymphoproliferative disease, J. Immunol. 174: 4551–4558, 2005.
Aplin, A. E., Gibb, G. M., Jacobsen, J. S., Gallo, J. M. and Anderton, B. H.: In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J. Neurochem. 67(2): 699–707, 1996.
Arai, Y., Suzuki, A., Mizuguchi, M. and Takashima, S.: Developmental and aging changes in the expression of amyloid precursor protein in Down syndrome brains. Brain Dev. 19(4): 290–294, 1997.
Arai, T., Ikeda, K., Akiyama, H., Shikamoto, Y., Tsuchiya, K., Yagishita, S., Beach, T., Rogers, J., Schwab, C. and McGeer, P. L.: Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick’s disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. (Berl.) 101(2): 167–173, 2001.
Arawaka, S., Hasegawa, H., Tandon, A., Janus, C., Chen, F., Yu, G., Kikuchi, K., Koyama, S., Kato, T., Fraser, P. E. and St. George-Hyslop, P.: The levels of mature glycosylated nicastrin are regulated and correlate with gamma-secretase processing of amyloid betaprecursor protein. J. Neurochem. 83(5): 1065–1071, 2002.
Arendash, G. W., King, D. L., Gordon, M. N., Morgan, D., Hatcher, J. M., Hope, C.L. and Diamond, D.M.: Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid pre-cursor protein and presenilin-1 transgenes. Brain Res. 891: 42–53, 2001.
Areosa, S. A. and Sherriff, F.: Memantine for dementia. Cochrane Database Syst. Rev. (3): CD003154, 2003.
Arias, E., Ales, E., Gabilan, N. H., Cano-Abad, M. F., Villarroya, M. Garcia, A. G. and Lopez, M. G.: Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotine acetylcholine receptors. J. Pharmacol. Exper. Therap. 310: 387–994, 2004.
Arias, E., Gallego-Sandin, S., Villarroya, M., Garcia, A. G. and Lopez, M. G.: Unequal protection afforded by the acetylcholinesterase inhibitors galantamine, donepezil and rivastigmine: role of nicotinic receptors of SH-SY5H neuroblastoma cells. J. Phamacol. Exper. Therap. 311, 2005.
Attenvill, C. K. and Bowen, D. M.: Neurotrophic factor for central cholinergic neurons is present in both normal and Alzheimer brain tissue. Acta Neuropthol. (Berlin) 69: 341–342, 1986.
Atwood, C. S., Perry, G., Smith, M. A.: Cerebral hemorrhage and amyloid-beta. Science 299(5609): 1014, 2003.
Auld, D. S., Kar, S. and Quirion, R.: Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link? TINS 21:43–49, 1998.
Austin, L., Arendash, G. W., Gordon, M. N., Diamond, D. M., DiCarlo, G., Dickey, C., Ugen, K. and Morgan, D.: Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. Behav. Neurosci. 117(3): 478–484, 2003.
Battistin, L. and Gerstenbrand, F., Eds.: “Aging Brain and Dementia,” Wiley-Liss, New York, 1990.
Becker, R. and Giacobini, E., Eds.: “Cholinergic Basis for Alzheimer Therapy,” Birkhauser, Boston, 1991.
Bender-Pape, T. L., Heinemann, A. W., Kelly, J. P., Giobbie Hurder, A. and Lundgren, S.: A measure of neurobehavioral functioning after coma. I. Theory, reliability and validity of the disorders of conscious ness scale. J. Rehabil. Res. Dev., 42: 1–17, 2005.
Berezovska, O., Ramdya, P., Skoch, J., Wolfe, M. S., Bacskai, B. J. and Hyman, B. T.: Amyloid precursor protein associates with a nicastrin-dependent docking site on the presenilin 1-gamma-secretase complex in cells demonstrated by fluorescence lifetime imaging. J. Neurosci. 23(11): 4560–4566, 2003.
Bian, F., Nath, R., Sobocinski, G., Booher, R. N., Lipinski, W.J., Callahan, M.J., Pack, A., Wang, K.K. and Walker, L. C. Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J. Comp. Neurol. 446(3): 257–266, 2002.
Bick, K., Amaducci L. and Pepeu, G.: “The Early Story of Alzheimer Disease,” Liviana Press, Padova, 1937.
Bielschowski, M.: Zur Kentniss der Alzheimerschen Krankheit. J. Psychol. Neurol. 18: 273–292, 1911.
Bjorkhem, I., Lutjohann, D., Diczfalusy, U., Stahle, L., Ahlborg, G. and Wahren, J.: Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J. Lipid Res. 39(8): 1594–1600, 1993.
Blacker, D.: Mild cognitive impairment—no benefit from vitamin E, little from donepezil. N. Engl. J. Med. 352: 2439–2441, 2005.
Blessed, G., Tomlison, B. E. and Roth, M.: The association between quantitative measures of dementia and senile changes in the cerebral grey matter of elderly subjects. Brit. J. Psychiatry 114: 797–811, 1968.
Blumenthal, H. T. and Premachandra, B. N.: Bridging the aging-disease dichotomy. I. The amyloidosis model. Perspect. Biol. Med. 33: 402–420, 1990.
Bodovitz, S. and Klein, W. L.: Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem.: 271(8): 4436–4440, 1996.
Boncristiano, S., Calhoun, M. E., Kelly, P. H., Pfeifer, M., Bondolfi, L., Stalder, M., Phinney, A. L., Abramowski, D., Sturchler-Pierrat, C., Enz, A., Sommer, B., Staufenbiel, M. and Jucker, M.: Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J. Neurosci. 22(8): 3234–3243, 2002.
Borchelt, D. R., Thinakaran, G., Eckman, C.B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C. M., Kim, G., Seekins, S., Yager, D., Slunt, H. H., Wang, R., Seeger, M., Levey, A. L, Gandy, S. E., Copeland, N. G., Jenkins, N. A., Price, D. L., Younkin, S. G. and Sisodia, S. S.: Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta 1-42/1-40 ratio in vitro and in vivo. Neuron 17(5): 1005–1013, 1996.
Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L. and Sisodia, S.S.: Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19(4): 939–945, 1997.
Bouillot, C., Prochiantz, A., Rougon, G. and Allinquant, B.: Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties. J. Biol. Chem. 271(13): 7640–7644, 1996.
Bowen, D. M., Smith, C. B., White, P. and Davison, A. N.: Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 49:459–495, 1976.
Boyle, P. A. and Malloy, P. F.: Treating apathy in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 17: 91–99, 2004.
Brion, J. P., Anderton, B. H., Authelet, M., Dayanandan, R., Leroy, K., Lovestone, S., Octave, J. N., Pradier, L., Touchet, N. and Tremp, G.: Neurofibrillary tangles and tau phosphorylation. Biochem. Soc. Symp. 2001(67): 81–88, 2001.
Bullock, B. P. and Habener, J. F.: Phosphorylation of the cAMP response element binding protein CREB by cAMP-dependent protein kinase A and glycogen synthase kinase-3 alters DNA-binding affinity, conformation, and increases net charge. Biochemistry 37(11): 3795–3809, 1998.
Burn, D. J. and McKeith, I. G.: Current treatment of dementia with Lewy bodies and dementia associated with Parkinson’s disease. Mov. Disord. 18,Supplt. 6: 872–879, 2003.
Bush, A. I.: The metallobiology of Alzheimer’s disease. Trends Neurosci. 26: 207–214, 2003.
Butcher, L. L. and Woolf, N.J.: Neurotrophic agents may exacerbate the pathologic cascade of Alzheimer’s disease. Neurobiol. Aging 10: 557–570, 1989.
Buxbaurn, J. D.: Animal models of Alzheimer’s disease. Neurosci. Facts 4: 1, 1993.
Buxbaum, J. D., Liu, K. N., Luo, Y., Slack, J. L., Stocking, K. L., Peschon, J. J., Johnson, R. S., Castner, B. J., Cerretti, D. P. and Black, R. A.: Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 273(43): 27765–27767, 1998.
Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D. R., Price, D. L. and Wong, P. C: BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 4(3): 233–234, 2001.
Cai, X. D., Golde, T. E., Younkin, S. G.: Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 259(5094): 514–516, 1993.
Cataldo, A. M., Bamett, J. L., Pieroni, C. and Nixon, R. A.: Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer’s disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J. Neurosci. 17(16): 6142–6151, 1997.
Chauhan, N. B.: Membrane dynamics, cholesterol metabolism and Alzheimer’s disease, J. Lipid Res. 44: 2019–2029, 2003.
Chauhan, N. B. and Siegel, G. J.: Reversal of amyloid beta toxicity in Alzheimer’s disease model Tg2576 by intraventricular antiamyloid beta antibody. J. Neurosci. Res. 69(1): 10–23, 2002.
Chauhan, N. B. and Siegel, G. J.: Effect of PPF and ALCAR on the induction of NGF-and p75-mRNA and on APP processing in Tg2576 brain. Neurochem. Int. 43(3): 225–233, 2003.
Chauhan, N. B. and Siegel, G.J.: Efficacy of anti-AΒ antibody isotypes used for intracerebroventricular immunization in TgCRNDS. Neurosci. Lett. 375: 143–147, 2005.
Chauhan, N. B., Siegel, G. J. and Feinstein, D. L.: Propentofylline attenuates tau hyperphosphorylation in Alzheimer’s Swedish mutant model Tg2576. Neuropharmacology.Jan; 48(1): 93–104, 2005.
Chauhan, N. B., Lichtor, T. and Siegel, G. J.: Aging potentiates Abeta-induced depletion of SNAP-25 in mouse hippocampus. Brain Res. 982(2): 219–227, 2003.
Chauhan, N. B., Siegel, G. J. and Feinstein, D. L.: Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRNDS brain. Neurochem. Res. 29: 1897–1911, 2004.
Cheng, S. V., Nadeau, J. H., Tanzi, R. E., Watkins, P. C., Jagadesh, J., Taylor, B. A., Haines, J. L., Sacchi, N. and Gusella, J. F.: Comparative mapping of DNA markers from the familial Alzheimer disease and Down syndrome regions of human chromosome 21 to mouse chromosomes 16 and 17. Proc. Natl. Acad. Sci. U.S.A. 85(16): 6032–6036, 1988.
Chemy, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y., Huang, X., Goldstein, L.E., Moir, R.D., Lim, J.T., Beyreuther, K., Zheng, H., Tanzi, R.E., Masters, C.L. and Bush, A. I.: Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron. 30: 665–676, 2001.
Chochina, S. V., Avdulov, N. A., Igbavboa, U., Cleary, J. P., O’Hare, E. O. and Wood, W. G.: Amyloid beta-peptide 1-40 increases neuronal membrane fluidity: role of cholesterol and brain region. J. Lipid Res. 42(8): 1292–1297, 2001.
Choi, E. K., Zaidi, N. F., Miller, J. S., Crowley, A. C., Merriam, D. E., Lilliehook, C., Buxbaum, J. D. and Wasco, W.: Calsenilin is a substrate for caspase-3 that preferentially interacts with the familial Alzheimer’s disease-associated C-terminal fragment of presenilin 2. J. Biol. Chem. 275(22): 19197–19204, 2001.
Chong, Y. H. and Sun, Y. H.: Amyloido genic processing of Alzheimer’s amyloid precursor protein in vitro and its modulation by metal ions and tacrine. Life Sci. 59: 545–557, 1996.
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I. and Selkoe, D. J.: Mutation of the beta-amyloid precursor protein in familial Alzheimer’s disease increases beta-protein production. Nature 360(6405): 672–674, 1992.
Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-Wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St. George Hyslop, P. and Selkoe, D. J.: Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3(1):67–72, 1997.
Committee on Chemical Toxicity and Aging: “Aging in Today’s Environment,” National Academy Press, Washington, D.C., 1987.
Cook, L. J., Ho, L. W., Wang, L., Terrenoir, E., Brayne, C., Evans, J. G., Xuereb, J., Cairns, N. J., Turic, D., Hollingwrth, P., Moore, P. J., Jehu, L., Archer, N., Walter, S., Foy, C., Edmondson, A., Powell, J., Lovestone, S., Williams, J. and Rubinsztein, D. C: Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer’s disease suggests choline acetyltransferase as a candidate deserving further study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 132B: 5–8, 2004.
Cottrell, B. A., Galvan, V., Banwait, S., Gorostiza, O., et al.: A pilot proteomic study of amyloid precursor interactors in Alzheimer’s disease. Ann Neurol. 58: 277–289, 2005.
Crisby, M., Carlson, L. A. and Winblad, B.: Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 16(3): 131–136, 2002.
Cross, D. A., Culbert, A. A., Chalmers, K. A., Facci, L., Skaper, S. D. and Reith, A. D.: Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. 77(1): 94–102, 2001.
Crowder, R. J. and Freeman, R. S.: Glycogen synthase kinase-3 beta activity is critical for neuronal death causedby inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J. Biol. Chem. 275(44): 34266–34271, 2000.
Cummings, J. L., Nadel, A., Masterman, D. and Cyrus, P.A.: Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer’s disease, J. Geriatr. Psychiatry Neurol. 14: 101–108, 2001.
D’Amico, M., Hulit, J., Amanatullah, D. F., Zafonte, B. T., Albanese, C., Bouzahzah, B., Fu, M., Augenlicht, L. H., Donehower, L. A., Takemaru, K.., Moon, R. T., Davis, R., Lisanti, M.P., Shtutman, M., Zhurinsky, J., Ben-Ze’ev, A., Troussard, A. A., Dedhar, S. and Pestell, R. G.: The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J. Biol. Chem. 275(42): 32649–32657, 2000.
Davies, P. and Maloney, A. J. F.: Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2: 1402, 1976.
Davies, J. P., Chen, F. W. and Ioannou, Y. A.: Transmembrane molecular pump activity of Niemann-Pick C1 protein. Science 290: 2295–2298, 2000.
Davis, K. L., Hollister, L. E. and Tinkleberg, J. R.: Physostigmine: effects on cognition and affect in normal subjects. Psychopharmacology 51: 23–27, 1976.
De Ferrari, G. V. and Inestrosa, N. C: Wnt signaling function in Alzheimer’s disease. Brain Res. Brain Res. Rev. 33(1): 1–12, 2000.
DeGiorgio, L. A., Shimizu, Y., Chun, H. S., Cho, B. P., Sugama, S., Jon, T.H. and Volpe, B. T.: APP knockout attenuates microglial activation and enhances neuron survival in substantia nigra compacta after axotomy. Glia. 38(2): 174–178, 2002.
De Jonghe, C., Esselens, C., Kumar-Singh, S., Craessaerts, K., Serneels, S., Checler, F., Annaert, W., Van Broeckhoven, C. and De Strooper, B.: Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum. Mol. Genet. 10(16): 1665–1671, 2001.
DeKosky, S.T.: Pathology and pathways of Alzheimer’s disease with an update on new developments in treatment. J. Am. Geriatr. Soc. 51(5), Supplt. Dementia: S314–320, 2003.
Dietschy, J. M. and Turley, S. D.: Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12(2): 105–112, 2001.
Dineley, K.T., Xia, X., Bui, D., Sweatt, J. D. and Zheng, H.: Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J. Biol. Chem. 277(25): 22768–22780, 2002.
Divry, P.: De la nature de l’alteration fibrillaire d’Alzheimer. J. Belge Neurol. Psychiat. 34: 197–201, 1934.
Doble, B. W. and Woodgett, J. R.: GSK-3: tricks of the trade for a multi-taskingkinase. J. Cell Sci. 116:1175–1186, 2003.
Dominguez, D., Tournoy, J., Hartmann, D., Huth, T., Cryus, K.., Deforce, S., Serneels, L., Camacho, I. E., Marjauy, E., Craessaerts, K., Roebroek, A. J., Schwake, M., D’Hooge, R., Back, P., Kalinke, U., Moechars, D., Alzheimer, C., Reiss, K., Saftig, P. and De Strooper, B.: Phenotypic and biochemical analyses of BACE1-and BACE2-deficient mice. J. Biol. Chem. 280: 30797–30806, 2005.
Drachman, D.A.: Central cholinergic system and memory. In: “Psychopharmacology: A Generation of Progress,” M. A. Lipton, A. DiMascio, and K. F. Killam, Ed., pp. 651–662, Raven Press, New York, 1978.
Drachman, D. A. and Leavitt, J.: Human memory and the cholinergic system—a relationship to aging? Arch. Neurol. Psychiat. 30: 113–121, 1974.
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C. M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., Morgan, D., Gordon, M. N., Holcomb, L., Refolo, L., Zenk, B., Hardy, J. and Younkin, S.: Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383(6602): 710–713, 1996.
Ehehalt, R., Keller, P., Haass, C., Thiele, C. and Simons, K.: Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160(1): 113–123, 2003.
Eriksen, J.L., Sagi, S.A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K.H., Koo, E. H. and Golde, T. E.: NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112(3): 440–449, 2003.
Enz, A., Amstutz, R., Bodekke, H., Gmelin, G. and Malanowski, J.: Brain selective inhibition of acetyl-cholinesterase: a novel approach to therapy for Alzheimer’s disease. In: “Cholinergic Function and Dysfunction,” A. C. Cuello, Ed., pp. 431–438, Elsevier, Amsterdam, 1993.
Esler, W. P., Kimberly, W. T., Ostaszewski, B. L., Ye, W., Diehl, T. S., Selkoe, D.J., Wolfe, M.S.: Activity-dependent isolation of the presenilin-gamma-secretase complex reveals nicastrin and a gamma substrate. Proc. Natl. Acad. Sci. U.S.A. 99(5): 2720–2725, 2002.
Etminan, M., Gill, S. and Samii, A.: Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ 327(7407): 128, 2003.
Evans, J. G.: Ageing and disease. In: “Research and the Ageing Population,” D. Evered and J. Whalen, Eds., Ciba Found. Symp. No. 124, Wiley, Chichester, 1988.
Fagan, A. M., Watson, M., Parsadanian, M., Bales, K. R., Paul, S. M. and Holtzman, D. M.: Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer’s disease. Neurobiol. Dis. 9(3): 305–318, 2002.
Farmery, M. R., Tjemberg, L. O., Pursglove, S. E., Bergman, A., et al.: Partial purification and characterization of γ-secretase from post-mortem human brain. J. Biol. Chem. 278: 24277–24284, 2003.
Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., Runz, H., Kuhl, S., Bertsch, T., von Bergmann, K., Hennerici, M., Beyreuther, K. and Hartmann, T.: Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 98(10): 5856–5861, 2001.
Ferrer, I., Barrachina, M. and Puig, B.: Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer’s disease. Pick’s disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol (Berl.) 104(6): 583–591, 2002.
Ferrer, I., Barrachina, M., Tolnay, M., Rey, M.J., Vidal, N., Carmona, M., Blanco, R. and Puig, B.: Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic brain disease. Brain Pathol. 13(1): 62–78, 2003a.
Ferrer, I., Pastor, P., Rey, M. J., Munoz, E., Puig, B., Pastor, E., Oliva, R. and Tolosa, E.: Tau phosphorylation and kinase activation in familial tauopathy linked to deln296 mutation. Neuropathol. Appl. Neurobiol. 29(1): 23–34, 2003b.
Finch, C. E. and Roth, G. S.: Biochemistry of Aging. In: “Basic Neurochemistry”, Sixth Edition, G. J. Siegel, B.W. Agranoff, R. W. Albers, S. K. Fisher, and M. D. Uhler, Eds., pp. 614–633, Philadelphia: Lippincott-Raven, 1999.
Fiol, C. J., Williams, J. S., Chou, C. H., Wang, Q. M., Roach, P. J. and Andrisani, O. M.: A secondary phosphorylation of CREB341 at Serl29 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. J. Biol. Chem. 269(51): 32187–32193, 1994.
Fischer, O.: Miliary Nekrosen mit drueszinger Wucherungen der Neurofibrillen, eine regelmaessige Veraenderung der Hirnrinde bei seniler Demenz. Monatsschrft. Psych. U. Neurol. 22: 361–372, 1907.
Fisher, A.: Muscarinic agonists for the treatment of Alzheimer’s disease: progress and perspectives. Eur. Opin. Invest. Drugs 6: 1395–1411, 1997.
Fisher, A., Brandeis, R., Haring, R., Eshar, N., Heldman, E., Karton, Y., Eisenberg, O., Meshulam, H., Marciano, D., Bar-Ner, N. and Pittel, Z.: Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer’s disease: an unifying hypothesis. In: “From Torpedo Electric Organ to Human Brain: Fundamental and Applied Aspects,” J. Massoulié, Ed., pp. 227–340, Elsevier, Amsterdam, 1998.
Fisher, A., Michaelson, D. M., Brandeis, R., Haring, R., Chapman, S. and Pittel, Z.: M1 muscarinic agonists as potential disease-modifying agents in Alzheimer’s disease. Rationale and perspectives. Ann. N.Y.Acad. Sci. 920: 315–320, 2000.
Foerstl, H. and Levy, R., Eds.: Introduction to Alzheimer’s paper “On certain diseases of Old Age,” Alpha Academic Press, London, 2: 71–73, 1991.
Forlenza, O. V., Spink, J. M., Dayanandan, R., Anderton, B. H., Olesen, O. F. and Lovestone, S.: Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J. Neural. Transm. 107(10): 1201–1212, 2000.
Frank, R. and Hargreaves, R.: Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2(7): 566–580, 2003.
Fraser, P. E., Yu, G., Levesque, L., Nishimura, M., Yang, D.S., Mount, H.T., Westaway, D. and St. George-Hyslop, P. H.: Presenilin function: connections to Alzheimer’s disease and signal transduction. Biochem.Soc.Symp. 2001(67): 89–100, 2001.
Frears, E. R., Stephens, D. J., Walters, C. E., Davies, H. and Austen, B. M.: The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 10(8): 1699–1705, 1999.
Fujita, M., Ichise, M., van Dyck, C. H., Zoghbi, S. S., Tamagnan, G., Mukhin, A. G., Bozkurt, A., Seneca, N., Tipre, D., DeNucci, C. C., Iida, H., Vaupel, D. B., Horti, A. G., Koren, A. O., Kimes, A.S., London, E. D., Seibyl, J.P., Baldwin, R. M. and Innis, R. B.: Quantification of nicotinic acetylcholine receptors in human brain using [1231]5-I-A-85380 SPET. Eur. J. Nucl. Med. Mol. Imaging 30: 1620–1619, 2003.
Fujiki, M., Kobayashi, H., Uchida, S., Inoue, R. and Ishii, K.: Neuroprotective effect of donepezil, anicotinic acetylcholine receptor activator, on cerebral infarction in rats. Brain Res. 1043: 2236–2241, 2005.
Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A. L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., Miller, R., Berry, R. W., Binder, L. I. and Cryns, V. L.: Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 100(17): 10032–10037, 2003.
Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373(6514): 523–527, 1995.
Gandy, S.: Eitrogen and neurodegeneration. Neurochem. Res. 28(7): 1003–1008, 2003.
Gandy, S., DeMattos R. B., Lemere, C. A., Heppner, F. L., Leerone, J., Aguzzi, A., Ershler, W. B., Dai, J., Fraser, P., St. George-Hyslop, P., Holtzman, D. M., Walker, L. C. and Keller, E. T.: Alzheimer Aa vaccination of Rhesus monkeys (Macaca Mulatta). Alzheimer Dis. Assoc.Disord. 303: 44–46, 2004.
Garrido, J. L., Godoy, J. A., Alvarez, A., Bronfman, M. and Inestrosa, N. C: Protein kinase C inhibits amyloid beta peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J. 16(14): 1982–1984, 2002.
Ghribi, O., Herman, M. M. and Savory, J.: Lithium inhibits Abeta-induced stress in endoplasmic reticulum of rabbit hippocampus but does not prevent oxidative damage and tau phosphorylation. J. Neurosci. Res.71(6): 853–862, 2003.
Giacobini, E.: Cholinergic receptors in human brain: effects of aging and Alzheimer’s disease. J. Neurosci. Res. 27: 548–560, 1990.
Giacobini, E.: The second generation of cholinesterase inhibitors: pharmacological aspects. In: “Cholinergic Basis for Alzheimer Therapy,” R. Becker and E. Giacobini, pp. 247–296, Birkhaeuser, Boston, 1991.
Giacobini, E.: Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: “Cholinesterases and Cholinesterase Inhibitors,” E. Giacobini, Ed. pp. 181–226, Martin Dunitz, London, 2000.
Giacobini, E., Ed.: “Butyrylcholinesterase. Its Function and Inhibitors,” Martin Dunitz, London, 2003a.
Giacobini, E.: Cholinergic function and Alzheimer’s disease. Int. J. Geriatr. Psychiatry 18,Supplt. 1: S1–S5, 2003b.
Giacobini, E. and Becker, R., Eds.:“Current Research in Alzheimer Therapy,” Taylor and Francis, New York, 1988.
Gil-Bea, F. J., Garcia-Alloza, M., Dominquez, J., Marcos, B. and Ramirez, M. J.: Evaluation of cholinergic markers in Alzheimer’s disease and in model of cholinergic deficits. Neurosci. Lett. 375: 37–41, 2005.
Glenner, G.: Amyloid deposits and amyloidosis. N. Engl. J. Med. 302: 1283–1292, 1980.
Glenner, G.: Editorial: reactive systemic amyloidosis in cystic fibrosis and other disorders associated with chronic inflammation. Arch. Pathol Lab. Med. 110: 873–877, 1986.
Glenner, G. G. and Wong, C. W.: Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloidprotein. Biochem. Biophys. Res. Commun. 120: 885–890, 1984a.
Glenner, G. G. and Wong, C. W.: Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebro-vascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122: 1131–1135, 1984b.
Glick, D.: The nature and significance of cholinesterase. In: “Comparative Biochemistry: Intermediate Metabolism of Fats, Carbohydrate Metabolism, Biochemistry of Choline,” H. B. Lewis, Ed., pp. 213–233, Jacques Cattell Press, Lancaster,Penn., 1941.
Glisson, S. N., Karczmar, A. G. and Barnes, L.: Cholinergic effects on adrenergic neurotransmitters in rabbit brain parts. Neuropharmacology 11: 465–477, 1972.
Glisson, S. N., Karczmar, A. G. and Barnes, L.: Effects of diisopropyl phosphorofluoridate on acetylcholine, cholinesterase and catecholamines of several parts of rabbit brain. Neuropharmacology 13: 623–632, 1974.
Gomez, S., Davies, P., Faivre-Bauman, A., Valade, D., Jeannin, C., Rondot, P. and Puymirat, J.: Acetylcholinesterase activity and somatostatin-like immunore-activity in lumbar cerebrospinal fluid of demented patients. In: “Alzheimer’s and Parkinson’s Diseases,” A. Fisher, I. Hanin, and C. Lachman, Eds., pp. 317–322, Plenum Press, New York, 1935.
Gottardi, C. J., Wong, E. and Gumbiner, B. M.: Ecadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J. Cell Biol. 153(5): 1049–1060, 2001.
Gotz, J., Chen, F., van Dorpe, J. and Nitsch, R. M.: Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 293(5534): 1491–1495, 2001.
Gray, C. W. and Patel, A. J.: Induction of beta-amyloid precursor protein isoform mRNAs by bFGF in astrocytes. Neuroreport 4(6): 811–814, 1993.
Grimes, C. A. and Jope, R. S.: CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J. Neurochem. 78(6): 1219–1232, 2001.
Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J.E. and Troncoso, J. C.: Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch. Pathol. Lab. Med. 125(4): 489–492, 2001.
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Gitaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al.: Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359(6393): 322–325, 1992a.
Haass, C., Koo, E. H., Mellon, A., Hung, A. Y. and Selkoe, D. J.: Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 557(6378): 500–503, 1992b.
Hailstones, D., Sleer, L. S., Parton, R. G. and Stanley, K. K.: Regulation of caveolin and caveolae by cholesterol in MDCK cells. J. Lipid Res. 39(2): 369–379, 1998.
Han, X., Cheng, H., Fryer, J. D., Fagan, A. M. and Holtzman, D. M.: Novel role for apolipoprotein E in the central nervous system: modulation of sulfatide content. J. Biol. Chem. 278(10): 8043–8051, 2003.
Handelmann, G. E., Boyles, J. K., Weisgraber, K. H., Mahley, R. W. and Pitas, R. E.: Effects of apolipo-protein E, beta-very low density lipoproteins, and cholesterol on the extension of neuntes by rabbit dorsal root ganglion neurons in vitro. J. Lipid Res. 33(11): 1677–1688, 1992.
Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J.P. and Anderton, B. H.: Glycogen synthase kinase-3 induces Alzheimer’s disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett. 147(1): 58–62, 1992.
Hardt, S. E. and Sadoshima, J.: Glycogen synthase kinase-3beta: a novel regulator of cardiac hyper-trophy and development. Circ. Res. 90(10): 1055–1063, 2002.
Haring, R., Fisher, A., Marciano, D., PitteL. Z., Kloog, Y., Zuckerman, A., Eshhar, N. and Heldman, E.: Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion. J. Neurochem. 71(5): 2094–2103, 1998.
Harkany, T., O’Mahoney, S. and Kelly, J. P.: Beta-amyloid {Phe [(So3H) 24] 25-35} in rat nucleus basalis induces behavioral dysfunctions, impairs learning and memory and disrupts cholinergic innervation. Behav. Brain Res. 90: 133–145, 1998.
Harper, S. J., Bilsland, J. G., Shearman, M. S., Zheng, H., Van der Ploeg, L. and Sirinathsinghji, D. J.: Mouse cortical neurones lacking APP show normal neurite outgrowth and survival responses in vitro. Neuroreport 9(13): 3053–3058, 1998.
Harrison, T. and Beher, D.: Gamma-secretase inhibitors—from molecular probes to new therapeutics? Prog. Med. Chem. 41: 99–127, 2003.
Hartman, R. E., Wozniak, D. F., Nardi, A., Olney, J. W., Sartorius, L. and Holtzman, D. M.: Behavioral phenotyping of GFAP-apoE3 and-apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer’s-like neuropathology. Exp. Neurol. 170(2): 326–344, 2001.
Hefti, F. and Weiner, W. J.: Nerve growth factor and Alzheimer’s disease. Ann. Neurol. 20: 275–281, 1986.
Hernandez, F., Borrell, J., Guaza, C., Avila, J. and Lucas, J.J.: Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J. Neurochem. 83(6): 1529–1533, 2002.
Herreman, A., Van Gassen, G., Bentahir, M., Nyabi, O., Craessaerts, K., Mueller, U., Annaert, W. and De Strooper, B.: Gamma-secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation. J. Cell Sci. 116, Pt. 6: 1127–1136, 2003.
Higuchi, K., Matsumara, A. and Honma, A.: Senile amyloidosis in senescence accelerated mice. Lab. Invest. 48: 231–240, 1983.
Hogan, D. B., Goldlist, B., Naglie, G. and Patterson, C: Comparison studies of cholinesterase inhibitors for Alzheimer’s disease. Lancet Neurol. 3: 622–626, 2004.
Howland, D.S., Savage, M. J., Huntress, F. A., Wallace, R. E., Schwartz, D. A., Loh, T., Melloni, R. H., Jr., DeGennaro, L. J., Greenberg, B. D., Siman, R., Swanson, M. E. and Scott, R. W.: Mutant and native human beta-amyloid precursor proteins in transgenic mouse brain. Neurobiol. Aging 16(4): 685–699, 1995.
Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G. Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A. and Mucke, L.: Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc. Natl. Acad. Sci. U.S.A. 96(6): 3228–3233, 1999.
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F. and Cole, G.: Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284): 99–102, 1996.
Hussain, I., Powell, D., Howlett, D. R., Tew, D. G., Meek, T. D., Chapman, C., Gloger, I. S., Murphy, K. E., Southan, C. D., Ryan, D. M., Smith, T. S., Simmons, D. L., Walsh, F. S., Dingwall, C. and Christie, G.: Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol. Cell. Neurosci. 14(6); 419–427, 1999.
Ikezu, T., Trapp, B.D., Song, K. S., Schlegel, A., Lisanti, M. P. and Okamoto, T.: Caveolae, plasma membrane microdomains for alpha-secretase-mediated processing of the amyloid precursor protein. J. Biol. Chem. 273(17): 10485–10495, 1998.
Ishii, T., Furuoka, H., Muroi, Y. and Nishimura, M.: Inactivation of integrin-linked kinase induces aberrant Tau phosphorylation via sustained activation of glycogen synthase kinase 3beta in N1E-115 neuro-blastoma cells. J. Biol. Chem. 278(29): 26970–26975, 2003.
Iqbal, K., Alonso Adel, C., El-Akkad, E., Gong, C. X., Haque, N., Khatoon, S., Pei, J. J., Tsujio, I., Wang, J. Z. and Grundke-Iqbal, I. Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. J. Mol. Neurosci. 19(1-2): 95–99, 2002.
Janus, C.: Vaccines for Alzheimer’s disease: how close are we? CNS Drugs. 17(7): 457–474, 2003.
Jick, H., Zomberg, G. L., Jick, S. S., Seshadri, S. and Drachman, D. A.: Statins and the risk of dementia. Lancet 356(9242): 1627–1631, 2000.
Jones, R. W.: Have cholinergic therapies reached their clinical boundary in Alzheimer’s disease? Int. J. Geriatr. Psychiatry 18,Supplt. 18: S7–S13, 2003.
Kakio, A., Nishimoto, S. I., Yanagisawa, K., Kozutsumi, Y. and Matsuzaki, K.: Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 276(27): 24985–24990, 2001.
Kamal, A., Almenar-Queralt, A., LeBlanc, J. F., et al.: Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 414: 643–648, 2001.
Kang, D. E., Soriano, S., Xia, X, Eberhart, C. G., De Strooper, B., Zheng, H., Koo, E. H.: Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell 110(6): 751–762, 2002.
Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., Multhaup, G., Beyreuther, K. and Muller-Hill, B.: The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325(6106): 733–736, 1987.
Karczmar, A. G.: Pharmacologic, toxicologie, and therapeutic properties of anticholinesterase agents. In: “Physiological Pharmacology,” W. S. Root and F. G. Hofman, Eds., vol. 3, pp. 163–322, Academic Press, New York, 1967.
Karczmar, A. G.: New roles for cholinergics in CNS disease. Drug Ther. 4: 31–42, 1979.
Karczmar, A. G.: SDAT models and their dynamics. In: “Cholinergic Basis for Alzheimer Therapy,” R. Becker and E. Giacobini, Eds., pp. 141–152, Birkhaeuser, Boston, 1991.
Karczmar, A. G.: Cholinergic substrates of cognition and organism-environment interaction. Prog. Neuropsychopharmacol. Biol. Psychiatry 19: 187–211, 1995.
Karczmar, A. G. and Dun, N. J.: Effects of anticholinesterases pertinent for SDAT treatment but not necessarily underlying their clinical effectiveness. In: “Current Research in Alzheimer Therapy,” E. Giacobini and R. Becker, Eds., pp. 15–29, Taylor and Francis, New York, 1988.
Kasa, P., Sr., Papp, H., Kasa, P., Jr., Pakaski, M. and Balaspiri, L.: Effects of amyloid-beta on cholinergic and acetylcholinesterase-positive cells in cultured basal forebrain neurons of embryonic rat brain. Brain Res. 998: 73–82, 2004.
Kawamura, Y., Kikuchi, A., Takada, R., Takada, S., Sudoh, S., Shibamoto, S., Yanagisawa, K. and Komano, H. Inhibitory effect of a presenilin 1 mutation on the Wnt signalling pathway by enhancement of beta-catenin phosphorylation. Eur. J. Biochem. 268(10): 3036–3041, 2001.
Kemp, P. M., Holmes, C., Hoffman, S., Wilkinson, S., Zivanovic, M., Thom, J., Bolt, L., Fleming, J. and Wilkinson, D. G.: A randomized placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 74: 1567–1570, 2003.
Kesavapany, S., Lau, K. F., McLoughlin, D. M., Brownlees, J., Ackerley, S., Leigh, P. N., Shaw, C. E and Miller, C. C: p35/cdk5 binds and phos-phorylates beta-catenin and regulates beta-catenin/ presenilin-1 interaction. Eur. J. Neurosci. 13(2): 241–247, 2001.
Kessler, R. M.: Imaging methods for evaluating brain function in man. Neurobiol. Aging 24,Supplt. 1: S21–S35, 2003.
Killick, R., Pollard, C.C., Asuni, A.A., Mudher, A. K., Richardson, J. C., Rupniak, H. T., Sheppard, P. W., Vamdell, I. M., Brion, J. P., Levey, A. I., Levy, O. A., Vestling, M., Cowburn, R., Lovestone, S. and Anderton, B. H.: Presenilin 1 independently regulates beta-catenin stability and transcriptional activity. J. Biol. Chem. 275(51): 48554–48561, 2001.
Kimberly, W. T., Xia, W., Rahmati, T., Wolfe, M. S. and Selkoe, D. J.: The trans membrane aspartates in presentilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. J. Biol. Chem. 275: 3173–3178, 2000.
Kimberly, W. T., La Voie, M. J., Ostaszewski, B. L., Ye, W., Wolfe, M. S. and Selkoe, D. J.: Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc. Natl. Acad. Sci. U.S.A. 100(11): 6382–6387, 2003.
Kinoshita, A., Whelan, C. M., Smith, C. J., Berezovska, O. and Hyman, B. T.: Direct visualization of the gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein: association with Fe65 and trans location to the nucleus. J. Neurochem. 82(4): 839–847, 2002.
Kitaguchi, N., Takahashi, Y., Tokushima, Y., Shiojiri, S. and Ito, H.: Novel precursor of Alzheimer’s disease amyloid protein shows protease inhibitory activity. Nature 331(6156): 530–532, 1988.
Klatzo, I., Wisniewski, H. M. and Streiker, E.: Experimental production of neurofibrillary degeneration. J. Neuropathol. Exp. Neurol. 24: 1187–1199, 1965.
Klimov, D. K. and Thirumalai, D.: Dissecting the assembly of abeta(16–22) amyloid peptides into antiparallel Beta sheets. Structure (Camb.) 11(3): 295–307, 2003.
Kojro, E., Gimpl, G., Lammich, S., Marz, W. and Fahrenholz, F.: Low cholesterol stimulates the non-amyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. U.S.A. 98(10): 5815–5820, 2001.
Koo, E. H. and Squazzo, S. L.: Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269(26): 17386–17389, 1994.
Kopan, R. and Goate, A.: A common enzyme connects notch signaling and Alzheimer’s disease. Genes Dev. 14(22): 2799–2806, 2000.
Kovacs, T., Cairns, N.J. and Lantos, P. L.: Beta-amyloid deposition and neurofibrillary tangle formation in the olfactory bulb in ageing and Alzheimer’s disease. Neuropathol. Appl. Neurobiol. 25(6): 481–491, 1999.
Kraepelin, E.: “Lehrbuch der Psychiatry,” II Band. Johann Ambrosius Barth Verlag, Leipzig, 1910.
Lang, T., Bruns, D., Wenzel, D., Riedel, D., Holroyd, P., Thiele, C. and Jahn, R.: SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. EMBO J 20(9): 2202–2213, 2001.
Lau, K. F., Miller, C. C., Anderton, B. H. and Shaw, P. C: Molecular cloning and characterization of the human glycogen synthase kinase-3beta promoter. Genomics 60(2): 121–128, 1999.
Laviolette, S. R. and van der Kooy, I.: The neurobiology of nicotine addiction: bridging the gap from molecules to behavior. Nat. Rev. Neurosci. 5: 55–65, 2004.
Lazarov, O., Morfini, G. A., Lee, E. B., Farah, M. H., Szodora, A., DeBeer, S. K., Koliatsos, V. E., King, S., Lee, V. M., Wong, P.C., Price, D. L., Brady, S. T. and ¡sodia, S.S.: Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus:revisited. J. Neurosci. 25: 2386–2395, 2005.
Lee, C. W., Lau, K. F., Miller, C. C. and Shaw, P. C: Glycogen synthase kinase-3 beta-mediated tauphos-phorylation in cultured cell lines. Neuroreport 14(2): 257–260, 2003.
Lee, H. J., Jung, K. M., Huang, Y. Z., Bennett, L. B., Lee, J. S., Mei, L. and Kim, T. W.: Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. J. Biol. Chem. 277(8): 6318–6323, 2002.
Lee, S. J., Liyanage, U., Bickel, P. E., Xia, W., Lansbury, P. T., Jr. and Kosik, K. S.: A detergent-insoluble membrane compartment contains A beta in vivo. Nat. Med. 4(6): 730–734, 1998.
Leissring, M. A., Yamasaki, T.R., Wasco, W., Buxbaum, J. D., Parker, I. and LaFerla, F. M.: Calsenilin reverses presenilin-mediated enhancement of calcium signaling. Proc. Natl. Acad. Sci. U.S.A. 97(15): 8590–8593, 2000.
Leissring, M. A., Murphy, M. P., Mead, T. R., Akbari, Y., Sugarman, M. C., Jannatipour, M., Anliker, B., Muller, U., Saftig, P., De Strooper, B., Wolfe, M. S., Golde, T. E. and LaFerla, F. M.: A physiologic signaling role for the gamma-secretase-derived intracellular fragment of APP. Proc. Natl. Acad. Sci. U.S.A. 99(7): 4697–4702, 2002.
Leroy, K., Boutajangout, A., Authelet, M., Woodgett, J. R., Anderton, B. H., Brion, J. P.: The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer’s disease. Acta Neuropathol. (Berl.) 103(2): 91–99, 2002.
Levites, Y., Amit, T., Mandel, S. and Youdim, M. B.: Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J. 17(8): 952–954, 2003.
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Paul Murphy, M., Baker, M., Yu, X., Duff, K., Hardy, J., Corral, A., Lin, W.L., Yen, S.H., Dickson, D. W., Davies, P., Hutton, M.: Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25(4): 402–405, 2000. Erratum in: Nat. Genet. 25(1): 127, 2000.
Lewis, J., Dickson, D. W., Lin, W. L., Chisholm, L., Corral, A., Jones, G., Yen, S. H., Sahara, N., Skipper, L., Yager, D., Eckman, C., Hardy, J., Hutton, M. and McGowan, E.: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293(5534): 1487–1491, 2001.
Li, W., Pi, R., Chan, H. H., Lee, N. T., Tsang, H. W., Pu, Y., Chang, D. C., Li, C., Luo, J., Li, Z., Xue, H., Carlier, P. R., Pang, Y., Tsim, K. W., Li, M. and Han, Y.: Novel dimeric AChE inhibitor Bis(7)-Tacrine but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking NMDA receptors. J. Biol. Chem., 280: 18179–18188, 2005.
Lilliehook, C., Chan, S., Choi, E. K., Zaidi, N. F., Wasco, W., Matison, M. P. and Buxbaum, J. D.: Calsenilin enhances apoptosis by altering endoplasmic reticulum calcium signaling. Mol. Cell. Neurosci. 19(4): 552–559, 2002.
Lin-Lee, Y. C., Kao, F. T., Cheung, P. and Chan, L.: Apolipoprotein E gene mapping and expression: localization of the structural gene to human chromosome 19 and expression of ApoE mRNA in lipoprotein-and non-lipoprotein-producing tissues. Biochemistry 24: 3751–3756, 1985.
Lipton, S. A.: Paradigm shift in NMDA receptor antagonist drug development. Molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer’s disease and other neurological disorders. J. Alzheimers Dis. 6,Supplt. 6: S61–S74, 2004.
Liu, F., Iqbal K., Grundke-Iqbal, I. and Gong, C. X.: Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett. 530(1-3): 209–214, 2002.
Lojkowska, W., Ryglewicz. D., Jedrzejczak, T., Mine, S., Jakubowska, T., Jarosz, H. and Bochynska, A. J.: The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer’s disease and vascular dementia. Neurol. Sci. 216: 119–126, 2003.
Lu, S. and Tune, L. E.: Chronic exposure to anticholinergic medication adversely affects the course of Alzheimer’s disease. Am. J. Geriatr. Psychiatry 11: 458–161, 2003.
Ludwig, F. C: Senescence: pathology facing medicine’s ultimate issue. Arch. Pathol. Lab. Med. 105: 445–451, 1981.
Luo, W. J., Wang, H., Li, H., Kim, B. S., Shah, S., Lee, H. J., Thinakaran, G., Kim, T. W., Yu, G. and Xu, H.: PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. J. Biol. Chem. 278(10): 7850–7854, 2003.
Luo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., Martin, L., Louis, J. C., Yan, Q., Richards, W. G., Citron, M. and Vassar, R.: Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 4(3): 231–232, 2001.
Maccioni, R. B., Otth, C., Concha, I.I. and Munoz, J. P.: The protein kinase Cdk5: structural aspects, roles in neurogenesis and involvement in Alzheimers pathology. Eur. J. Biochem. 268(6): 1513–1527, 2001.
Mahley, R. W.: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240(4852): 622–630, 1988.
Maltese, W. A., Wilson, S., Tan, Y., Suomensaari, S., Sinha, S., Barbour, R. and McConlogue, L.: Retention of the Alzheimer’s amyloid precursor fragment C99 in the endoplasmic reticulum prevents formation of amyloid beta-peptide. J. Biol. Chem. 275(23): 20267–20279, 2001.
Marambaud, P., Shioi, J., Serban, G., Georgakopoulos, A., Samer, S., Nagy, V., Baki, L., Wen, P., Efthimiopoulos, S., Shao, Z., Wisniewski, T. and Robakis, N. K.: A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J. 21(8): 1948–1956, 2002.
Marks, N. and Berg, M. J.: APP processing enzymes (secretases) as therapeutic targets: insights from the use of transgenics (Tgs) and transfected cells. Neurochem. Res. 28(7): 1049–1062, 2003.
Martin, A.: Antioxidant vitamins E and C and risk of Alzheimer’s disease. Nutr. Rev. 61(2): 69–73, 2003.
Maruyama, K., Kametani, F., Usami, M., Yamao-Harigaya, W.and Tanaka, K.: “Secretase,” Alzheimer amyloid protein precursor secreting enzyme is not sequence-specific. Biochem. Biophys. Res. Commun. 179(3): 1670–1676, 1991.
Masliah, E.: Mechanisms of synaptic dysfunction in Alzheimer’s disease. Histol. Histopathol. 10(2): 509–519, 1995.
Masliah, E., Mallory, M., Ge, N. and Saitoh, T.: Amyloid precursor protein is localized in growing neuntes of neonatal rat brain. Brain Res. 593: 323–337, 1992.
Mason, N. S. and Mathis, C. A.: Positron emission tomography radio chemistry. Neuroimaging Clin. N. Am. 13: 671–687, 2003.
Massa, S. M., Xie, Y. and Longo, F. M.: Alzheimer’s therapeutics: neurotrophin small molecule mimetics. J. Mol. Neurosci. 19: 107–111, 2002.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L. and Beyreuther, K.: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82(12): 4245–4249, 1985.
Mazzucchelli, M., Porello, E., Viletti-Pietra, C., Govoni, S. and Racchi, M.: Characterization of the effect of ganstigmine (CHF2819) on amyloid precursor protein metabolism in SH-SY5Y neuroblas-toma cells. J. Neural Transm. 110: 935–947, 2003.
McGeer, P. L., McGeer, E. G., Suzuki, J., Dolman, C. E. and Nagai, T.: Aging, Alzheimer’s disease and the cholinergic system of the basal forebrain. Neurology 34; 741–745, 1984.
McGeer, P. L., Schulzer, M. and McGeer, E. G.: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology 47(2): 425–432, 1996.
McKinney, M. and Jacksonville, M. C: Brain cholinergic vulnerability: relevance to behavior and disease. Biochem. Pharmacol. 70: 1115–1124, 2005.
McMenemey, W. H.: Alois Alzheimer and his disease. In: “Alzheimer’s Disease,” G. E. Wolstenholme and M. O’Connor, Eds. Ciba Found., Churchill, London, 1970.
Mesulam, M. M.: Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer’s disease. In: “Cholinesterases and Cholinesterase Inhibitors,” E. Giacobini, Ed., pp. 121–137, Martin Dunitz, London, 2000.
Mesulam, M. M.: The cholinergic lesion of Alzheimer’s disease: Pivotal factor or side show? Learn. Mem. 11:43–49, 2004.
Mesulam, M. M., Shaw, P., Mash, D. and Weintraub, S.: Cholinergic nucleus basalis tauopathy emerges early in The aging-MCI-AD continuum. Ann. Neurol. 55: 815–828, 2004.
Mills, J. and Reiner, P. B.: Regulation of amyloid precursor protein cleavage. J. Neurochem. 72(2): 443–460, 1999.
Mills, J., Digicaylioglu, M., Legg, A. T., Young, C. E., Young, S. S., Barr, A. M., Fletcher, L., O’ Connor, T. P. and Dedhar, S.: Role of integrin-linked kinase in nerve growth factor-stimulated neurite outgrowth. J. Neurosci. 23(5): 1638–1648, 2003.
Minett, T. S., Thomas, A., Wilkinson, L. M., Daniel. S. L., Sanders, J., Richardson, J., Littlewood, E., Myint, P., Newby, J. and McKeith, I. G.: What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int. J. Geriatr. Psychiatry 18: 988–993, 2003.
Mizuno, T., Nakata, M., Naiki, H., Michikawa, M., Wang, R., Haass, C. and Yanagisawa, K.: Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J. Biol. Chem. 274(21): 15110–15114, 1999.
Moechars, D., Dewachter, I., Lorent, K., Reverse, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C. V., Checler, F., Godaux, E., Cordeil, B. and Van Leuven, F.: Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274(10): 6483–6492, 1999.
Monsonego, A., Zota, V., Karni, A., Krieger, J. I., Bar-Or, A., Bitan, G., Budson, A. E., Sperling, R., Selkoe, D. J. and Weiner, H. L.: Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112(3): 415–422, 2003.
Morfini, G., Pigino, G., Beffert, U., Busciglio, J. and Brady, S. T.: Fast axonal transport misregulation and Alzheimer’s disease. Neuromolecular Med. 2(2): 89–99, 2002.
Mori, C., Spooner, E. T., Wisniewsk, K. E., Wisniewski, T. M., Yamaguch, H., Saido, T. C., Tolan, D. R., Selkoe, D. J., Lemere, C. A.: Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid. 9(2): 88–102, 2002.
Moran, M. A., Mufson, E. J. and Gomez-Ramos, P.: Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer’s brains. Acta Neuropathol. 85:362–369, 1993.
Morgan, D.: Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochem. Res. 28(7): 1029–1034, 2003.
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcox, D., Connor, K., Hatcher, J., Hope, C., Gordon, M. and Arendash, G. W.: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408(6815): 982–985, 2000.
Morishima-Kawashima, M. and Ihara, Y.: The presence of amyloid beta-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry 37(44): 15247–15253, 1998.
Morohashi, Y., Hatano, N., Ohya, S., Takikawa, R., Watabiki, T., Takasugi, N., Imaizumi, Y., Tomita, T. and Iwatsubo, T.: Molecular cloning and characterization of CALP/KChIP4, a novel EF-hand protein interacting with presenilin 2 and voltage-gated potassium channel subunit Kv4. J. Biol. Chem. 277(17): 14965–14975, 2002.
Morris, J. C. and Price, A L.: Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer’s disease. J. Mol. Neurosci. 17(2): 101–118, 2001.
Morris, R. G.: “A Cognitive Neuropsychology of Alzheimer Dementia,” Oxford U. Press, Now York, 1996
Mudher, A., Chapman, S., Richardson, J., Asuni, A., Gibb, G., Pollard, C., Killick, R., Iqbal, T., Raymond, L., Varndell, I., Sheppard, P., Makoff, A., Gower, E., Soden, P. E., Lewis, P., Murphy, M., Golde, T. E., Rupniak, H. T., Anderton, B. H. and Lovestone, S.: Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase. J. Neurosci. 21(14): 4937–4995, 2001.
Nathan, B. P., Bellosta, S., Sanan, D. A., Weisgraber, K. H., Mahley, R. W. and Pitas, R. E.: Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264(5160): 850–852, 1994.
Naureckiene, S., Sleat, D. E., Lackland, H., Fensom, A., Vanier, M.T., Wattiaux, R., Jadot, M. and Lobel, P.: Identification of HE1 as the second gene of Niemann-Pick C disease. Science 290: 2298–2301, 2000.
New York Times, Editorial: Do Alzheimer’s drugs work? Editorial Desk, Section 4, p. 10, April 11, 2004.
Nicolaou, M., Song, Y. Q., Sato, C. A., Orlacchio, A., Kawarai, T., Medeiros, H., Liang, Y., Sorbi, S., Richard, E., Rogaev, E. I., Moliaka, Y., Bruni, A. C., Jorge, R., Percy, M., Duara, R., Farrer, L. A., St. George-Hyslop, P. and Rogaeva, E. A.: Mutations in the open reading frame of the beta-site APP cleaving enzyme (BACE) locus are not a common cause of Alzheimer’s disease. Neurogenetics 3(4): 203–206, 2001.
Nishimura, M., Yu, G., Levesque, G., Zhang, D. M., Ruel, L., Chen, F., Milman, P., Holmes, E., Liang, Y., Kawarai, T., Jo, E., Supala, A., Rogaeva, E., Xu, D. M., Janus, C., Levesque, L., Bi, Q., Duthie, M., Rozmahel, R., Mattila, K.., Lannfelt, L., Westaway, D., Mount, H. T., Woodgett, J., St. George-Hyslop, P., et al. Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex. Nat. Med. 5(2): 164–169, 1999.
Nitsch, R. M., Slack, B. E., Wurtan, R. J. and Growdon, J. H.: Release of amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258: 304–307, 1992.
Nitsch, R. M., Rossner, S. and Albrecht, C.: Muscarinic acetylcholine receptors activate the acetylcholinesterase gene promoter. J. Physiol. 25: 257–264, 1998.
Noble, W., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J., Gaynor, K.., LaFrancois, J., Wang, L., Kondo, T., Davies, P., Burns, M., Veeranna, Nixon, R., Dickson, D., Matsuoka, Y., Ahlijanian, M., Lau, L. F. and Duff, K.: Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38(4): 555–565, 2003.
Nordberg, A.: The effect of cholinesterase inhibitors studied with brain imaging. In: “Cholinesterases and Cholinesterase Inhibitors,” E. Giacobini, Ed., pp. 237–247, Martin Dunitz, London, 2000.
Nordberg, A.: Toward an early diagnosis and treatment of Alzheimer’s disease. Int. Psychogeriatr. 15: 223–227, 2003.
Nordberg, A.: Functional studies of cholinergic activity in normal and Alzheimer’s disease states by imaging technique. Prog. Brain Res. 145: 301–310, 2004.
Nordberg, A. and Winblad, B.: Brain nicotinic and muscarinic receptors in normal aging and dementia. In: “Alzheimer’s and Parkinson’s Diseases,” A. Fisher, I. Hanin, and C. Lachman, Eds., pp. 95–108, Plenum Press, New York, 1986.
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y. and LaFerla, F. M.: Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39(3): 409–421, 2003.
Ohkubo, N., Lee, Y. D., Morishima, A., Terashima, T., Kikkawa, S., Tohyama, M., Sakanaka, M., Tanaka, J., Maeda, N., Vitek, M. P. and Mitsuda, N.: Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3beta cascade. FASEB J. 17(2): 295–297, 2003.
Oltersdorf, T., Fritz, L. C., Schenk, D. B., Lieberburg, I., Johnson-Wood, K. L., Beattie, E. C., Ward, P. J., Blacher, R. W., Dovey H. F. and Sinha, S.: The secreted form of the Alzheimer’s amyloid precursor protein with the Kunitz domain is protease nexin-II. Nature 341(6238): 144–147, 1989.
O’Neill, C., Cowbum, R. F., Bonkale, W. L., Ohm, T. G., Fastbom, J., Carmody, M. and Kelliher, M.: Dysfunctional intracellular calcium homoeostasis: a central cause of neurode generation in Alzheimer’s disease. Biochem. Soc. Symp. 2001(67): 177–194, 2001.
Orozco, C., de Los Rios, C., Arias, E., Leon R. Garcia, A. G., Marco, J. L., Villarroya, M. and Lopez, M. G.: ITH4012 (ethyl 5-amino-6,7,8,9-tetrahydro-2-methyl-4-phenylbenzol(1,8) naphtythyridine-3-carboxylate. a novel acetylcholinesterase inhibitor with “calcium-pro motor” and neuroprotective properties. J. Pharmacol. Exper. Therap. 310: 987–994, 2004.
Oyama, F., Sawamura, N., Kobayashi, K., Morishima-Kawashima, M., Kuramochi, T., Ito, M., Tomita, T., Maruyama, K., Saido, T. C., Iwatsubo, T., Capell, A., Walter, J., Grunberg, J., Ueyama, Y., Haass, C. and Ihara, Y.: Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid beta protein 42 in the brain. J. Neurochem. 71(1): 313–322, 1998.
Pakaski, M., Rakonczay, Z., Fakla, I., Papp, H. and Kasa, P.: In vitro effects of metrifonate on neuronal precursor protein processing and protein kinase C level. Brain Res. 863: 266–270, 2000.
Palmert, M. R., Podlisny, M. B., Golde, T. E., Cohen, M. L., Kovacs, D. M., Tanzi, R. E., Gusella, J. F., Whitehouse, P. J., Witker, D. S., Oltersdorf, T., et al.: The beta amyloid protein precursor: mRNAs, membrane-associated forms, and soluble derivatives. Prog. Clin. Biol. Res. 317: 971–984, 1989.
Palop, J. J. Jones, B., Kekonius, L., Chin, J., Yu, G. Q., Raber, J., Masliah, E. and Mucke, L.: Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer’s disease-related cognitive deficits. Proc. Natl. Acad. Sci. U.S.A. 100(16): 9572–9577, 2003.
Pap, M. and Cooper, G. M.: Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J. Biol. Chem. 273(32): 19929–19932, 1998.
Papp, H., Pakaski, M., Kasa, P.: Presenilin-1 and the amyloid precursor protein are transported bidirectionally in the sciatic nerve of adult rat. Neurochem. Int. 41(6): 429–435, 2002.
Parkin, E. T., Turner, A. J. and Hooper, N. M.: Amyloid precursor protein, although partially detergent-insoluble in mouse cerebral cortex, behaves as an atypical lipid raft protein. Biochem. J. 344, Pt. 1: 23–30, 1999.
Pasternak, S. H., Bagshaw, R. D., Guiral, M., Zhang, S., Ackerley, C. A., Pak, B. J., Callahan, J. W. and Mahuran, D. J.: Presenilin-1, nicastrin, amyloid pre-cursor protein, and gamma-secretase activity are colocalized in the lysosomal membrane. J. Biol. Chem. 278(29): 26687–26694, 2003.
Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P. and Tsai, L. H.: Conversion of p35 to p25 deregulates Cdk5 activity and promotes neuro de generation. Nature 402(6762): 615–622, 1999.
Pei, J. J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B. and Cowburn, R. F.: Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58(9): 1010–1019, 1999.
Pei, J. J., Khatoon, S., An, W. L., Nordlinder, M., Tanaka, T., Braak, H., Tsujio, I., Takeda, M., Alafuzoff, I., Winblad, B., Cowburn, R. F., Grundke-Iqbal, I. and Iqbal, K..: Role of protein kinase B in Alzheimer’s neuro fibrillary pathology. Acta Neuropathol. (Berl.) 105(4): 381–392, 2003.
Perez, M., Ribe, E., Rubio, A., Lim, F., et al.: Characterization of a double (amyloid precursor proteintau) transgenic: tauphosphorylation and aggregation. Neuroscience 130: 339–347, 2005.
Perry, E. K., Gibson, P. H., Blessed, G., Perry, R. H. and Tomlison, B. E.: Neurotransmitter enzyme abnormalities in senile dementia. J. Neurol. Sci. 34: 247–265, 1977.
Perry, E. K.., Ziabreva, I., Perry, R. H., Aarsland, D. and Ballard, C.: Absence of cholinergic deficits in “pure” vascular dementia. Neurology 64: 132–133, 2005.
Perusini, G.: über klinisch und histologisch eigenmartige psychische Erkränkung der späteren Lebensalters. In: “Histologische und Histopataologische Arbeiten,” F. Nissl and A. Alzheimer, Eds., Bd. 3, pp.197–351, 1910.
Perusini, G.: Sul valore nosografico di alcuni reperti istopatologici caraetteristici per la senilita. Revista Ital. Neuropatol. Psichiat. Elettroter. 4: 145–151, 1911.
Peters, B. and Levin, H. S.: Effects of physostigmine and lecithin on memory in Alzheimer’s disease. Ann. Neurol. 6: 219–221, 1979.
Pfeifer, L. A., White, L. R., Ross, G. W., Petrovitch, H. and Launer, L. J.: Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 58(11): 1629–1634, 2002a.
Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M. and Jucker, M.: Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298(5597): 1379, 2002b.
Phiel, C. J., Wilson, C. A., Lee, V. M. and Klein, P. S.: GSK-3alpha regulates production of Alzheimer,s disease amyloid-beta peptides. Nature 423(6938): 435–439, 2003.
Piccini, A., Russo, C., Gliozzi, A., Relini, A., et al.: Β-Amyloid is different in normal aging and in Alzheimer disease. J. Biol. Chem. 280: 34186–34192, 2005.
Pigino, G., Morfini, G., Pelsman, A., Matison, M. P., Brady, S. T. and Busciglio, J.: Alzheimer’s presenilin 1 mutations impair kinesin-based axonal transport. J. Neurosci. 23(11): 4499–4508, 2003.
Pike, L. J. and Miller, J. M.: Cholesterol depletion delocalizes phosphatidylinositol bisphosphate and inhibits hormone-stimulated phosphatidylinositol turnover. J. Biol. Chem. 273(35): 22298–22304, 1998.
Poirier, J.: Apolipoprotein E and Alzheimer’s disease: a role in amyloid catabolism. Ann N. Y. Acad. Sci. 924: 81–90, 2000.
Poirier, J., Baccichet, A., Dea, D. and Gauthier, S.: Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 55(1): 81–90, 1993.
Pomponi, M. and Marta, M.: On the suggestion of Dr. Alzheimer I examined the following four cases. Dedicated to Gaetano Perusi. Aging Clin. Exp. Res. 5: 135–139, 1992.
Ponte, P., Gonzalez-DeWhitt, P., Schilling, J., Miller, J., Hsu, D., Greenberg, B., Davis, K., Wallace, W., Lieberburg, I. and Fuller, F.: A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature 331(6156): 525–527, 1988.
Price, D. L.: The Macaca mulatta model of Alzheimer’s disease. Neurosci. Facts 4: 17–18, 1993.
Profenno, L. A. and Tariot, P. N.: Pharmacologic management of agitation in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 17: 65-77, 2005.
Puglielli, L., Konopka, G., Pack-Chung, E., Ingano, L. A., Berezovsky O., Hyman, B. T., Chang, T. Y., Tanzi, R. E. and Kovacs, D. M.: Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3(10): 905–912, 2001.
Rabidazeh, S., Oh, S., Ord, J., Zhong, L.-T., Yang, J., Bittner, C. M., Butcher, L. L. and Dresdesen, D. E.: Induction of apoptosis by low-affinity NGF receptor. Science 261: 345–348, 1993.
Rabizadeh, S., Bittner, C. M., Butcher, L. L. and Bredesen, D. E.: Expression of the low affinity growth factor receptor enhances beta-amyloid peptide toxicity. Proc. Natl. Acad. Sci. U.S.A. 91: 10703–10706, 1994.
Racchi, M., Baetta, R., Salvietti, N., Ianna, P., Franceschini, G., Paoletti, R., Fumagalli, R., Govoni, S., Trabucchi, M. and Soma, M.: Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem. J. 322, Pt. 3: 893–893, 1997.
Redlich, E.: über miliare Sklerose der Hirnrinde bei seniler Atrophie. Jahrbuche Psych. u. Neurol. 17: 361–372, 1898.
Roberds, S. L., Anderson, J., Basi, G., Bienkowski, M. J., Branstetter, D. G., Chen, K.S., Freedman, S. B., Frigon, N. L., Games, D., Hu, K.., Johnson-Wood, K., Kappenman, K. E., Kawabe, T. T., Kola, I., Kuehn, R., Lee, M., Liu, W., Motter, R., Nichols, N. F., Power, M., Robertson, D. W., Schenk, D., Schoor, M., Shopp, G.M., Shuck, M. E, Sinha, S., Svensson, K. A., Tatsuno, G., Tintrup, H., Wijsman, J., Wright, S. and McConlogue, L.: BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer’s disease therapeutics. Hum. Mol. Genet. 10(12): 1317–1324, 2001.
Rodal, S. K., Skretting, G., Garred, O., Vilhardt, F., van Deurs, B. and Sandvig, K..: Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol. Biol. Cell. 10(4): 961–974, 1999.
Rogawski, M. A. and Wenk, G. L.: The neuropharmacological basis for the use of memantine in treatment of Alzheimer’s disease. CNS Drug Rev. 9(3): 275–308, 2003.
Rohan de Silva, H.A., Jen, A., Wickenden, C., Jen, L.S., Wilkinson, S. L. and Patel, A. J.: Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes. Brain Res. Mol. Brain Res. 41(1–2): 147–156, 1997.
Roses, A. D., Saunders, A. M., Corder, E. H., Pericak-Vance, M. A., Han, S. H., Einstein, G., Hulette, C., Schmechel, D. E., Holsti, M., Huang, D.,et al.: Influence of the susceptibility genes apolipoprotein Eepsilon 4 and apolipoprotein E-epsilon 2 on the rate of disease expressivity of late-onset Alzheimer’s disease. Arzneimittelforschung. 45(3A): 413–417, 1995.
Rossner, S., Ueberham, U., Schliebs, R., Perez-Polo, J. R. and Bigl, V.: The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog. Neurobiol. 56(5): 541–569, 1998.
Roush, W.: Live long and prosper? Science 273: 42–46, 1996.
Runz, H., Rietdorf, J., Tomic, I., de Bernard, M., Beyreuther, K., Pepperkok, R. and Hartmann, T.: Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J. Neurosci. 22(5): 1679–1689, 2002.
Russell, R. W.: Brain “transplants,” neurotrophic factors and behavior. Alzheimer Dis. Assoc. Disord. 2: 77–95, 1988.
Russo, C., Schettini, G., Saido, T. C., Hulette, C., Lippa, C., Lannfelt, L., Ghetti, B., Gambetti, P., Tabaton, M., Teller, J. K..: Presenilin-1 mutations in Alzheimer’s disease. Nature 405(6786): 531–532, 2000.
Sabate, R., Gallardo, M. and Estelrich, J.: An autocatalytic reaction as a model for the kinetics of the aggregation of beta-amyloid. Biopolymers 71(2): 190–195, 2003.
Sarker, K. P. and Lee, K. Y.: L6 myoblast differentiation is modulated by Cdk5 via the PI3K-Akt-p70s6K signaling pathway, Oncogene. 23: 6064, 2004.
Saunders, A. M.: Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. J. Neuropathol. Exp. Neurol. 59(9): 751–758, 2000.
Sawamura, N., Gong, J. S., Garver, W. S., Heidenreich, R. A., Ninomiya, H., Ohno, K., Yanagisawa, K. and Michikawa, M.: Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick Type C mice. J. Biol. Chem. 276: 10314–10319, 2001.
Sayas, C. L., Avila, J. and Wandosell, F.: Regulation of neuronal cytoskeletonby lysophosphatidic acid: role of GSK-3. Biochim.Biophys. Acta 1582(1–3): 144–153, 2002.
Saykin, A. J., Wishart, H. A., Rabin, L. A., Flashmen, L. A., McHugh, T. L., Mamot, A. C. and Santulli, R. B.: Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 127: 1574–1583, 2004.
Sbema, G., Saez-Valero, J. and Li, Q.-X.: Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal segment (CT100) of the beta-amyloid protein precursor of Alzheimer’s disease. J. Neurochem. 71: 723–731, 1998.
Schenk, D.: Amyloid-beta immunotherapy for Alzheimer’s disease: the end of the beginning. Nat. Rev. Neurosci. 3(10): 824–828, 2002.
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D. and Younkin, S.: Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat. Med. 2(8): 864–870, 1996.
Schmaier, A. H., Dahl, L. D., Rozemuller, A. J., Roos, R. A., Wagner, S. L., Chung, R. and Van Nostrand, W. E.: Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa. J. Clin. Invest. 92(5): 2540–2545, 1993.
Schneider, I., Reverse, D., Dewachter, I., Ris, L., Caluwaerts, N., Kuiperi, C., Gilis, M., Geerts, H., Kretzschmar, H., Godaux, E., Moechars, D., Van Leuven, F. and Herms, J.: Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J. Biol. Chem. 276(15): 11539–11544, 2001.
Schroeder, F., Nemecz, G., Wood, W. G., Joiner, C., Morrot, G., Ayraut-Jarrier, M. and Devaux, P. F.: Transmembrane distribution of sterol in the human erythrocyte. Biochim. Biophys. Acta 1066(2): 183–192, 1991.
Seguchi, K., Kataoka, H., Uchino, H., Nabeshima, K. and Koono, M.: Secretion of protease nexin-II/ amyloid beta protein precursor by human colorectal carcinoma cells and its modulation by cytokines/ growth factors and proteinase inhibitors. Biol. Chem. 380(4): 473–483, 1999.
Selkoe, D. J.: Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer’s disease. Annu. Rev. Cell Biol. 10: 373–403, 1994.
Selkoe, D. J., Abraham, C. R., Podlisny, M. B. and Duffy, L. K.: Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer’s disease. J. Neurochem. 46(6): 1820–1834, 1986.
Selkoe, D.J., Yamazaki, T., Citron, M., Podlisny, M.B., Koo, E. H., Teplow, D. B. and Haass, C.: The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann. N. Y. Acad. Sci. 777: 57–64, 1996.
Selkoe, D. J. and Lansbury, P. J., Jr.: Biochemistry of Alzheimer’s disease and prion diseases. In: “Basic Neurochemistry,” Sixth Edition, G. J. Siegel, B. W. Agranoff, R. W. Albers, S. K. Fisher, and M. D. Uhler, Eds., pp. 950–968, Lippincott-Raven, Philadelphia, 1999.
Sengupta, A., Wu, Q., Grundke-Iqbal, I., Iqbal, K. and Singh, T. J.: Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol. Cell Biochem. 167(1–2): 99–105, 1997.
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher. M., Whaley, J., Swindlehurst, C., et al.: Isolation and quantification of soluble Alzheimer’s beta-peptide from biological fluids. Nature 359(6393): 325–327, 1992.
Shen, Z.-X.: The significance of the activity of CSF cholinesterases in dementias. Med. Hypotheses 47: 363–376, 1996.
Sheng, J. G., Price, D. L. and Koliatsos, V. E.: The beta-amyloid-related proeteins presenilins 1 and BACE1 are axonally transported to nerve terminals in the brain. Exp. Neurol. 184: 1053–1057, 2003.
Siegel, G. J. and Chauhan, N. B.: Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain. Brain Res. Brain Res. Rev. 33(2–3): 199–227, 2000.
Siman, R. and Velji, J.: Localization of presenilin-nicastrin complexes and gamma-secretase activity to the trans-Golgi network. J. Neurochem. 84(5): 1143–1153, 2003.
Simchowicz, T.: Histologische Sytudien über die senile Demenz. Nissl-Alzheimer Arbeiten 4: 267–444, 1911.
Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G. and Simons, K.: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U.S.A. 95(11): 6460–6464, 1998.
Simons, M., Keller, P., Dichgans, J. and Schulz, J. B.: Cholesterol and Alzheimer’s disease: is there a link? Neurology 57(6): 1089–1093, 2001.
Sisodia, S. S.: Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl. Acad. Sci. U.SA. 89(13): 6075–6079, 1992.
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., Jacobson-Croak, K., Jewett, N., Keim, P., Knops, J., Lieberburg, I., Power, M., Tan, H., Tatsuno, G., Tung, J., Schenk, D., Seubert, P., Suomensaari, S. M., Wang, S., Walker, D., Zhao, J., McConlogue, L. and John, V.: Purification and cloning of amyloid precursor protein beat-secretase from human brain. Nature 402: 537–540, 1999.
Sisodia, S. S., Koo, E. H., Hoffman, P. N., Perry, G. and Price, D. L.: Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system. J. Neurosci. 13(7): 3136–3142, 1993.
Skovronsky, D. M., Moore, D. B., Milla, M. E., Doms, R. W. and Lee, V. M.: Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-Golgi network. J. Biol. Chem. 275(4): 2568–2575, 2000.
Smith, M. A., Drew, K. L., Nunomura, A., Takeda, A., Hirai, K., Zhu, X., Atwood, C. S., Raina, A. K., Rottkamp, C. A., Sayre, L. M., Friedland, R. P. and Perry, G.: Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs? Neurochem. Int. 40(6): 527–531, 2002.
Smith, R. P., Higuchi, D.A. and Broze, G.J., Jr.: Platelet coagulation factor XIa-inhibit or, a form of Alzheimer amyloid precursor protein. Science 248(4959): 1126–1128, 1990.
Song, D. H., Dominguez, L, Mizuno, J., Kaut, M., Mohr, S. C. and Seldin, D. C.: CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling. J. Biol. Chem. 278(26): 24018–24025, 2003.
Song, J.H., Wang, C.X., Song, D. K., Wang, P., et al.: Interferon gamma induces neurite outgrowth by up-regulation of p35 neuron-specific cyclin-dependent kinase 5 activator via activation of ERK 1/2 pathway. J Biol. Chem. 280: 12896–12901, 2005.
Soriano, S., Kang, D. E., Fu, M., Pestell, R., Chevallier, N., Zheng, H. and Koo, E. H.: Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing. J. Cell Biol. 152(4): 785–794, 2001.
Steinhilb, M. L., Turner, R. S. and Gaut, J. R.: ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways. J. Neurochem. 80(6): 1019–1028, 2002.
Stine, W. B., Jr., Dahlgren, K. N., Krafft, G. A. and LaDu, M. J.: In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278(13): 11612–11622, 2003.
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S. and Roses, A. D.: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl.Acad. Sci. U.S.A. 90(5): 1977–1981, 1993.
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K. H., Mistl, C., Rothacher, S., Ledermann, B., Burki, K., Frey, P., Paganetti, P. A., Waridel, C., Calhoun, M. E., Jucker, M., Probst, A., Staufenbiel, M. and Sommer, B.: Two amyloidprecursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U.S.A. 94(24): 13287–13292, 1997.
Subtil, A., Gaidarov, I., Kobylarz, K., Lampson, M. A., Keen, J. H. and McGraw, T. E.: Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc. Natl.Acad. Sci. U.S.A. 96(12): 6775–6780, 1999.
Suh, Y. H. and Checler, F.: Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer’s disease. Pharmacol. Rev. 54(3): 469–525, 2002.
Suhara, T., Magrane, J., Rosen, K., Christensen, R., Kim, H.S., Zheng, B., McPhie, D. L., Walsh, K. and Querfurth, H.: Abeta42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signaling-dependent mechanism. Neurobiol. Aging 24(3): 437–451, 2003.
Sun, M. K. and Alkon, D. L.: Cerebral hypoperfusion and amyloid-induced synergistic impairment of hippocampal CA1 synapticefficacy andspatial memory in young adult rats. J. Alzheimers Dis. 6: 355–366, 2004.
Sun, X., Sato, S., Murayama, O., Murayama, M., Park, J. M., Yamaguchi, H. and Takashima, A.: Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci. Lett. 321(1–2): 61–64, 2002.
Suzuki, N., Cheung, T. T., Cai, X. D., Odaka, A., Otvos, L., Jr., Eckman, C., Golde, T.E. and Younkin, S. G.: An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264(5163): 1336–1340, 1994.
Svensson, A.-L. and Giacobini, E.: Cholinesterase inhibitors do more than inhibit cholinesterase. In: “Cholinesterases and Cholinesterase Inhibitors,” E. Giacobini, Ed., pp. 227–235, Martin Dunitz, London, 2000.
Swarthout, J. T., Tyson, D. R., Jefcoat, S. C. Jr., Partridge, N. C. and Efcoat, S. C., Jr.: Induction of transcriptional activity of the cyclic adenosine monophosphate response element binding protein by parathyroid hormone and epidermal growth factor in osteoblastic cells. J. Bone Miner. Res. 17(8): 1401–1407, 2002. Erratum in: J. Bone Miner. Res. 17(10): 1917, 2002.
Takashima, A., Yamaguchi, H., Noguchi, K., Michel, G., Ishiguro, K., Sato, K., Hoshino, T., Hoshi, M. and Imahori, K.: Amyloid beta peptide induces cyto-plasmic accumulation of amyloid protein precursor via tau protein kinase I/glycogen synthase kinase-3 beta in rat hippocampal neurons. Neurosci. Lett. 198(2): 83–86, 1995.
Takashima, A., Noguchi, K., Michel, G., Mercken, M., Hoshi, M., Ishiguro, K. and Imahori, K.: Exposure of rat hippocampal neurons to amyloid beta peptide (25–35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci. Lett. 203(1): 33–36, 1996.
Takashima, A., Honda, T., Yasutake, K., Michel, G., Murayama, O., Murayama, M., Ishiguro, K. and Yamaguchi, H.: Activation of tau protein kinase I/ glycogen synthase kinase-3beta by amyloid beta peptide (25–35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res. 31(4): 317–323, 1993a.
Takashima, A., Murayama, M., Murayama, O., Kohno, T., Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M., Yamaguchi, H., Sugihara, S. and Wolozin, B.: Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc. Natl. Acad. Sci. U.S.A. 95(16): 9637–9641, 1998b.
Takemaru, K. I. and Moon, R.T.: The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J. Cell Biol. 149(2): 249–254, 2000.
Tanaka, Y., Hanya, H., Sakurai, H., Takasaki, M. and Abe, K..: Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer’s disease patients. Dement. Geriatr. Cogn. Disord. 16: 119–1125, 2003.
Tandon, A. and Fraser, P.: The presenilins. Genome Biol. 3(11): reviews 3014, 2002.
Tanemura, K.., Murayama, M., Akagi, T., Hashikawa, T., Tominaga, T., Ichikawa, M., Yamaguchi, H. and Takashima, A.: Neurode generation with tau accumulation in a transgenic mouse expressing V337M human tau. J. Neurosci. 22(1): 133–141, 2002.
Tanzi, R. E, Bird, E. D., Latt, S. A. and Neve, R. L.: The amyloid beta protein gene is not duplicated in brains from patients with Alzheimer’s disease. Science 238(4827): 666–669 1987.
Tanzi, R. E, McClatchey, A. I., Lamperti, E. D., Villa-Komaroff, L., Gusella, J. F. and Neve, R. L.: Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s disease. Nature 331(6156): 528–530, 1988.
Tatebayashi, Y., Miyasaka, T., Chui, D. H., Akagi, T., Mishima, K.., Iwasaki, K.., Fujiwara, M., Tanemura, K.., Murayama, M., Ishiguro, K.., Planel, E., Sato, S., Hashikawa, T. and Takashima, A.: Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc. Natl. Acad. Sci. U.S.A. 99(21): 13896–13901, 2002.
Teller, J. K., Russo, C., DeBusk, L. M., Angelini, G., Zaccheo, D., Dagna-Bricarelli, F., Scartezzini, P., Bertolini, S., Mann, D. M., Tabaton, M. and Gambetti, P.: Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down’s syndrome. Nat. Med. 2(1): 93–95, 1996.
Terry, R. D., Masliah, E. and Hansen, L. A.: The neuro-pathology of Alzheimer disease and the structural basis of its cognitive alterations. In: “Alzheimer Disease,” Second Edition, R. D. Terry, R. Katzman, K. L. Bick, and S. S. Sisodia, Eds., pp. 187–206, Lippincott, Williams and Wilkins, Philadelphia, 1999.
Thal, L. J., Fuld, P. A., Masur, D. M. and Sharpless, N. S.: Oral physostigmine and lecithin improve memory in Alzheimer’s disease. Ann. Neurol. 13: 491–496, 1983.
Thal, L. J., Grundman, B., Berg, J., Ernstrom, K., Margolin, E., Pfeiffer, E., Weiner, M. F., Zamrini, E. and Thomas, R. G.: Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology 61: 1498–1502, 2003.
Thiel, C. M.: Cholinergic modulation of learning and memory in the human brain as detected with functional neuroimaging. Neurobiol. Learn. Mem. 80: 233–244, 2003.
Tomlison, B. E.: Plaques, tangles and Alzheimer’s disease. Psychol. Med. 12: 449–459, 1982.
Tractenberg, R. E., Gamst, A., Thomas, R. G., Patterson, M., Schneider, L. S. and Thal, L.J.: Investigating emergent symptomatology as an outcome measure in a behavioral study of Alzheimer’s disease. J. Neuropsychiatry Clin. Neurosci. 14: 303–310, 2002.
Troy, C. M., Rabacchi, S. A., Hohl, J. B., Angelastro, J. M., Greene, L. A. and Shelanski, M. L.: Death in the balance: alternative participation of the caspase-2 and-9 pathways in neuronal death induced by nerve growth factor deprivation. J. Neurosci. 21(14): 5007–5016, 2001. Erratum in: J. Neurosci. 21(16): 1b, 2001.
Tsukada, H., Nishiyama, S., Fukumoto, D., Ohba, H., Sato, K. and Kakiuchi, T.: Effects of acute acetyl-cholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: functional imaging of the conscious monkey brain using animal PET in combination with micro dialysis. Synapse 52: 1–10, 2004.
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H.S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., Tong, G., Potkin, S. G., Fallon, J., Hansen, L., Mufson, E. J., Kordower, J. H., Gall, C. and Conner, J.: A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11: 551–555, 2005.
Tyson, D. R., Swarthout, J. T., Jefcoat, S. C. and Partridge, N. C: PTH induction of transcriptional activity of the cAMP response element-binding protein requires the serine 129 site and glycogen synthase kinase-3 activity, but not casein kinase II sites. Endocrinology 143(2): 674–682, 2002.
Umans, L., Serneels, L., Lorent, K.., Dewachter, I., Tesseur, I., Moechars, D. and Van Leuven, F.: Lipo-protein receptor-related protein in brain and in cultured neurons of mice deficient in receptor-associated protein and transgenic for apolipoprotein E4 or amyloid precursor protein. Neuroscience 94(1): 315–321, 1999.
Utton, M. A., Vandecandelaere, A., Wagner, U., Reynolds, C. H., Gibb, G. M., Miller, C. C., Bayley, P. M., Anderton, B. H.: Phosphorylation of tau by glycogen synthase kinase 3beta affects the ability of tauto promote microtubule self-assembly. Biochem. J. 323, Pt. 3: 741–747, 1997.
Van Gassen, G., De Jonghe, C., Nishimura, M., Yu, G., Kuhn, S., St. George-Hyslop, P. and Van Broeckhoven, C.: Evidence that the beta-catenin nuclear translocation assay allows for measuring presenilin 1 dysfunction. Mol. Med. 6(7): 570–580, 2000.
Van Nostrand, W. E, Wagner, S. L., Suzuki, M., Choi, B.H., Farrow, J.S., Geddes, J.W., Cotman, C.W.and Cunningham, D. D.: Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. Nature 341(6242): 546–549, 1989.
Van Nostrand, W. E., Wagner, S. L., Farrow, J. S. and Cunningham, D. D.: Immunopurification and protease inhibitory properties of protease nexin-2/amyloid beta-protein precursor. J. Biol. Chem. 265(17): 9591–9594, 1990.
Van Nostrand, W. E., Schmaier, A. H., Neiditch, B.R., Siegel, R. S., Raschke, W. C., Sisodia, S. S. and Wagner, S. L.: Expression, purification, and characterization of the Kunitz-type proteinase inhibitor domain of the amyloid beta-protein precursor-like protein-2. Biochim. Biophys. Acta 1209(2): 165–170, 1994.
Van Nostrand, W. E., Melchor, J. P., Cho, H. S., Greenberg, S. M. and Rebeck, G. W.: Pathogenic effects of D23N Iowa mutant amyloid beta-protein. J. Biol. Chem. 276(35): 32860–32866, 2001.
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. C., Collins, F., Treanor, J., Rogers, G. and Citron, M.: Betasecretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735–741, 1999.
Vogelsberg-Ragaglia, V., Trojanowski, J. Q., Lee, V. M.-Y. In: “Alzheimer Disease,” Second Edition, R. D. Terry, R. Katzman, K.L. Bick, and S.S. Sisodia, Eds., pp. 359–372, Lippincott, Williams and Wilkins, Philadelphia, 1999.
Von Koch, C. S., Zheng, H., Chen, H., Trumbauer, M., Thinakaran, G., van der Ploeg, L. H., Price, D. L. and Sisodia, S. S.: Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. Neurobiol. Aging 18(6): 661–669, 1997.
Wagner, M. R., Keane, D. M., Melchor, J. P., Auspaker, K. R., Van Nostrand, W. E.: Fibrillar amyloid beta-protein binds protease nexin-2/amyloid beta-protein precursor: stimulation of its inhibition of coagulation factor XIa. Biochemistry 39(25): 7420–7427, 2000.
Wagner, U., Utton, M., Gallo, J. M. and Miller, C. C.: Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J. Cell Sci. 109, Pt. 6: 1537–1543, 1996.
Wagner, U., Brownlees, J., Irving, N. G., Lucas, F. R., Salinas, P. C. and Miller, C. C: Overexpression of the mouse dishevelled-1 protein inhibits GSK-3beta-mediated phosphorylation of tau in transfected mammalian cells. FEBS Lett. 411(2–3): 369–372, 1997.
Waschuk, S. A., Elton, E. A., Darabie, A. A., Fraser, P. E. and McLaurin, J. A.: Cellular membrane composition defines A beta-lipid interactions. J. Biol. Chem. 276(36): 33561–33568, 2001.
Weksler, M. E., Relkin, N., Turkenich, R., LaRusse, S., Zhou, L. and Szabo, P.: Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than do healthy elderly individuals. Exp. Gerontol. 37: 943–948, 2002.
Whitehouse, P. J., Price, D. L., Clark, A. W., Jr., Coyle, J. T. and DeLong, M. R.: Alzheimer’s disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10: 122–126, 1981.
Whitehouse, P. J., Price, D. L., Struble, R. G., Clark, A. W., Coyle, J. T. and DeLong, M. R.: Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 215: 1237–1239, 1982.
Whitehouse, P. J., Martino, A. M., Antuono, P. G., Lowenstein, P. R., Coyle, J. T., Price, D. L. and Kellar, K. J.: Nicotinic acetylcholine binding sites in Alzheimer’s disease. Brain Res. 371: 146–151, 1986.
Wild-Bode, C., Yamazaki, T., Capell, A., Leimer, U., Steiner, H., Ihara, Y. and Haass, C.: Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. J. Biol. Chem. 272(26): 16085–16088, 1997.
Wilson, C. A., Doms, R. W., Zheng, H. and Lee, V. M.: Presenilins are not required for A beta 42 production in the early secretory pathway. Nat. Neurosci. 5(9): 849–855, 2002.
Wisniewski, H. M.: Clinical, pathological and biochemical aspects of Alzheimer’s disease. In: “Alzheimer’s and Parkinson’s Diseases,” A. Fisher, I. Hanin and C. Lachman, Eds., pp. 25–36, Plenum Press, New York, 1987.
Wolfe, M.S. and Kopan, R.: Intramembrane proteolysis: theme and variations. Science 305: 1119–1123, 2004.
Wolfe, M. S. and Selkoe, D. J.: Biochemistry. Intramembrane proteases—mixing oil and water. Science 296(5576): 2156–2157, 2002.
Wolfe, M.S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., Selkoe, D. J.: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398(6727): 513–517, 1999.
Wolozin, B. and Davis, P.: Alzheimer-related neuronal protein A68:specificity and distribution. Ann. Neurol. 22:521–526, 1987.
Wolozin, B., Kellman, W., Rousseau, P., Celesia, G. G. and Siegel, G.: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57: 1439–1443, 2000.
Wong, P. C., Cai, H., Borchelt, D. R. and Price, D. L.: Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics. J. Mol. Neurosci. 17(2): 233–257, 2001.
Wong, P. L., Li, T. and Price, D.L.: Neurobiology of Alzheimer’s Disease. In: “Basic Neurochemistry: Molecular, Cellular and Medical Aspects Aspects,” G.J. Siegel, R. N. Albers, S. T. Brady, D. L. Price, Eds., 7th edition. Chap. 47, London: Elsevier/ Academic Press, 2006.
Woodgett, J. R.: Judging a protein by more than its name: GSK-3. Sci STKE. 2001(100): RE12, 2001.
Woolf, N.J., Gould, E. and Butcher, L. L.: Nerve growth factor receptor is associated with cholinergic neurons of the basal forebrain but not the pontomesencephalon. Neuroscience 30: 30–45, 1989.
Wu, C., Butz, S., Ying, Y. and Anderson, R. G.: Tyrosine kinase receptors concentrated in caveolae-like domains from neuronal plasma membrane. J. Biol. Chem. 272(6): 3554–3559, 1997.
Wurtman, R. J.: Alzheimer’s disease. Sci. Amer. 252: 62–74, 1985.
Wynn, Z. J. and Cummings, J. L.: Cholinesterase inhibitor therapies and neuropsychiatrie manifestations of Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 17: 100–108, 2004.
Xie, G., Gunn, R. N., Dagher, A., Daloze, T., Plourde, G., Backman, S. B., Diksic, I. and Fiset, P.: PET quantification of muscarinic cholinergic receptors with [N-metyl]-benztropine and application to studies of propofol-induced unconsciousness in healthy human volunteers. Synapse 51: 91–101, 2004.
Xu, D., Joglekar, A.P., Williams, A. L. and Hay, J. C: Subunit structure of a mammalian ER/Golgi SNARE complex. J. Biol. Chem. 275(50): 39631–39639, 2000.
Yamazaki, T., Chang, T. Y., Haass, C. and Ihara, Y.: Accumulation and aggregation of amyloid betaprotein in late endosomes of Niemann-pick Type C cells. J. Biol. Chem. 276: 4454–4460, 2001.
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashier, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., Carter, D. B., Tomasselli, A. G., Parodi, L. A., Heinrikson, R. L. and Gurney, M. E.: Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity. Nature 402(6761): 533–537, 1999.
Yanagisawa, K.., Odaka, A., Suzuki, N. and Ihara, Y.: GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer’s disease. Nat. Med. 1(10): 1062–1066, 1995.
Yip, C. M. and McLaurin, J.: Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption. Biophys. J. 80(3): 1359–1371, 2001.
Yip, C. M., Elton, E. A., Darabie, A. A., Morrison, M. R. and McLaurin, J.: Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis and neurotoxicity. J. Mol. Biol. 311(4): 723–734, 2001.
Yoshiike, Y., Chui, D. H., Akagi, T., Tanaka, N. and Takashima, A.: Specific compositions of amyloidbeta peptides as The determinant of toxic betaaggregation. J. Biol. Chem. 278(26): 23648–23655, 2003.
Yoshimura, T., Kawano, Y., Arimura, N., Kawabata, N., et al.: GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120: 137–149, 2005.
Yuan, J. and Yankner, B. A.: Caspase activity sows the seeds of neuronal death. Nat. Cell Biol. 1(2): E44–45, 1999.
Zaidi, N. F., Berezovska, O., Choi, E. K., Miller, J. S., Chan, H., Lilliehook, C., Hyman, B. T., Buxbaum, J. D. and Wasco, W.: Biochemical and immunocytochemical characterization of calsenilin in mouse brain. Neuroscience 114(1): 247–263, 2002.
Zannis, V. I. and Breslow, J. L.: Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry 20(4): 1033–1041, 1981.
Zheng, Y.-L., Kesavapany, S., Gravell, M., Hamilton, R. S., et al.: A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. The EMBO Journal 24: 209–220, 2005.
Zhou, H., Pfeifer, U. and Linke, R.: Generalized amyloidosis from beta 2-microglobulin, with caecal perforation after long-term haemodialysis. Virchows Arch. A Pathol. Anat. Histopathol. 419(4): 349–353, 1991.
Zhu, X., Lee, H. G., Raina, A. K., Perry, G. and Smith, M. A.: The role of mitogen-activated protein kinase pathways in Alzheimer’s disease. Neurosignals 11(5): 270–281, 2002.
Zimmermann, M., Gardoni, F., Marcello, E., Colciaghi, F., Borroni, B., Pardovani, A., Cattabeni, F. and Di Luca, M.: Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J. Neurochem. 90: 1489–1499, 2004.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Siegel, G.J., Chauhan, N., Karczma, A.G. (2007). Links Between Amyloid and Tau Biology in Alzheimer’s Disease and Their Cholinergic Aspects. In: Karczmar, A.G. (eds) Exploring the Vertebrate Central Cholinergic Nervous System. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-46526-5_10
Download citation
DOI: https://doi.org/10.1007/978-0-387-46526-5_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-28223-7
Online ISBN: 978-0-387-46526-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)